Characteristics of Clinical Trials to Support Approval of Orphan vs Nonorphan Drugs for Cancer
June 8, 2011 | Journal Article
More stringent evaluation of orphan drug trials is recommended to ensure safety and efficacy.
You are now viewing 1 - 9 of 9 results
June 8, 2011 | Journal Article
More stringent evaluation of orphan drug trials is recommended to ensure safety and efficacy.
October 1, 2010 | Journal Article
As comparative effectiveness research becomes a more prominent feature of clinical medicine, investigators and policy-makers would do well to seek lessons from prior examples of this type of research.
July 1, 2011 | Journal Article
Older patients—the most complex and expensive patients—are not adequately represented in randomized controlled trials.
March 21, 2011 | Story
Study by RWJF Clinical Scholars reveals that seniors are often excluded from trials, leaving doctors without critical data they need to treat their patients.
July 1, 2008 | Journal Article
This article examines whether integrating depression treatment into care for hypertension improves adherence to antidepressant and antihypertensive medications, depression outcomes and blood pressure control among older primary care patients.
September 16, 2008 | Journal Article
This study compares the use of massage therapy to relieve pain and other symptoms to simple touch therapy for terminally ill individuals.
January 1, 2006 | Journal Article
Type 2 diabetes affects 8 percent of U.S. adults, as well as a growing number of youth. Increased prevalence of diabetes will cause a serious increase in early morbidity, health care costs and lost productivity. There is now substantial evidence tha ...
January 4, 2011 | Human Capital Blog Post
RWJF Scholars in Health Policy Research National Program Director Alan B. Cohen, Sc.D., had a letter in the December 29, 2010 New York Times (Avastin: Judging the Risks vs. Benefits), noting that Food & Drug Administration (FDA) approval of new drug ...
August 19, 2008 | Journal Article
Seeding trials are clinical studies conducted by pharmaceutical companies designed to seem as if they answer a scientific question, but primarily fulfill marketing objectives they have not been described in detail.